Last reviewed · How we verify
Telbivudine, Adefovir dipivoxil
Telbivudine and adefovir dipivoxil are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus replication by inhibiting viral DNA polymerase.
Telbivudine and adefovir dipivoxil are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus replication by inhibiting viral DNA polymerase. Used for Chronic hepatitis B infection, HBeAg-positive chronic hepatitis B, HBeAg-negative chronic hepatitis B.
At a glance
| Generic name | Telbivudine, Adefovir dipivoxil |
|---|---|
| Also known as | Sebivo, LDT |
| Sponsor | Third Affiliated Hospital, Sun Yat-Sen University |
| Drug class | Nucleoside/nucleotide reverse transcriptase inhibitor |
| Target | Hepatitis B virus DNA polymerase / reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Telbivudine is a thymidine nucleoside analog that inhibits HBV reverse transcriptase and reduces viral DNA synthesis. Adefovir dipivoxil is a nucleotide analog prodrug that, when converted to adefovir, inhibits HBV DNA polymerase. Both agents suppress viral replication and reduce hepatitis B viral load in infected patients.
Approved indications
- Chronic hepatitis B infection
- HBeAg-positive chronic hepatitis B
- HBeAg-negative chronic hepatitis B
Common side effects
- Elevated creatine kinase
- Lactic acidosis
- Hepatic flare
- Nephrotoxicity (adefovir)
- Myopathy
Key clinical trials
- Carvedilol for Prevention of Esophageal Varices Progression (NA)
- Extension Study of Carvedilol RCT Study (NA)
- Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients
- Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy
- A Two-year Study of Telbivudine in HBeAg Negative Hepatitis (PHASE4)
- Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine (PHASE3)
- EFFORT Further Extension Study (PHASE4)
- Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: